Rational use of cetuximab in the treatment of advanced non-small cell lung cancer

References

• JemalASiegelRWardECancer statisticsCA Cancer J Clin200858719618287387
   PubMed Web of Science ®Google Scholar
• JemalAThunMJRiesLAAnnual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco controlJ Natl Cancer Inst20081001672169419033571
   PubMed Web of Science ®Google Scholar
• GoldstrawPCrowleyJChanskyKThe IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumoursJ Thorac Oncol2007270671417762336
   PubMed Web of Science ®Google Scholar
• GreeneFPageDFlemingIAJCC Cancer Staging Manual6th edNew YorkSpringer-Verlag2002
   Google Scholar
• ArriagadaRBergmanBDunantACisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancerN Engl J Med200435035136014736927
   PubMed Web of Science ®Google Scholar
• DouillardJYRosellRDe LenaMAdjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trialLancet Oncol2006771972716945766
   PubMed Web of Science ®Google Scholar
• ScagliottiGVFossatiRTorriVRandomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancerJ Natl Cancer Inst2003951453146114519751
   PubMed Web of Science ®Google Scholar
• WallerDPeakeMDStephensRJChemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung TrialEur J Cardiothorac Surg20042617318215200998
   PubMed Web of Science ®Google Scholar
• WintonTLivingstonRJohnsonDVinorelbine plus cisplatin vs observation in resected non-small-cell lung cancerN Engl J Med20053522589259715972865
   PubMed Web of Science ®Google Scholar
• StraussGMHerndonJE2ndMaddausMAAdjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study GroupsJ Clin Oncol2008265043505118809614
   PubMed Web of Science ®Google Scholar
• WestHAlbainKSCurrent standards and ongoing controversies in the management of locally advanced non-small cell lung cancerSemin Oncol20053228429215988683
   PubMed Web of Science ®Google Scholar
• EaganRTFrytakSRichardsonRLA randomized comparative trial of sequential versus alternating cyclophosphamide, doxorubicin, and cisplatin and mitomycin, lomustine, and methotrexate in metastatic non-small-cell lung cancerJ Clin Oncol19886582826714
   PubMed Web of Science ®Google Scholar
• CarteiGCarteiFCantoneACisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancerJ Natl Cancer Inst1993857948008387607
   PubMed Web of Science ®Google Scholar
• MattsonKMaasiltaPTammilehtoLTrimetrexate and cyclophosphamide for metastatic inoperable nonsmall cell lung cancerSemin Oncol19881532372835817
   PubMed Web of Science ®Google Scholar
• Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study GroupJ Natl Cancer Inst19999166729890172
   PubMed Web of Science ®Google Scholar
• AndersonHHopwoodPStephensRJGemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung CancerBr J Cancer20008344745310945489
   PubMed Web of Science ®Google Scholar
• RansonMRWhiteSThatcherNManagement of elderly patients with lung cancerCurr Oncol Rep20002909511122829
   PubMedGoogle Scholar
• SandlerABNemunaitisJDenhamCPhase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancerJ Clin Oncol20001812213010623702
   PubMed Web of Science ®Google Scholar
• WozniakAJCrowleyJJBalcerzakSPRandomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group studyJ Clin Oncol199816245924659667264
   PubMed Web of Science ®Google Scholar
• KellyKCrowleyJBunnPAJrRandomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non – small-cell lung cancer: a Southwest Oncology Group trialJ Clin Oncol2001193210321811432888
   PubMed Web of Science ®Google Scholar
• ScagliottiGVDe MarinisFRinaldiMPhase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancerJ Clin Oncol2002204285429112409326
   PubMed Web of Science ®Google Scholar
• SchillerJHHarringtonDBelaniCPComparison of four chemotherapy regimens for advanced non-small-cell lung cancerN Engl J Med2002346929811784875
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med20063552542255017167137
   PubMed Web of Science ®Google Scholar
• ReckMvon PawelJZatloukalPPhase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AvailJ Clin Oncol2009271227123419188680
   PubMed Web of Science ®Google Scholar
• ScagliottiGVParikhPvon PawelJPhase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancerJ Clin Oncol2008263543355118506025
   PubMed Web of Science ®Google Scholar
• LustbergMBEdelmanMJOptimal duration of chemotherapy in advanced non-small cell lung cancerCurr Treat Options Oncol20078384617634834
   PubMedGoogle Scholar
• SocinskiMAStinchcombeTEDuration of first-line chemotherapy in advanced non small-cell lung cancer: less is more in the era of effective subsequent therapiesJ Clin Oncol2007255155515718024862
   PubMed Web of Science ®Google Scholar
• SalomonDSBrandtRCiardielloFEpidermal growth factor-related peptides and their receptors in human malignanciesCrit Rev Oncol Hematol1995191832327612182
   PubMed Web of Science ®Google Scholar
• FordACGrandisJRTargeting epidermal growth factor receptor in head and neck cancerHead Neck200325677312478546
   PubMed Web of Science ®Google Scholar
• MendelsohnJTargeting the epidermal growth factor receptor for cancer therapyJ Clin Oncol2002201S13S12235219
   PubMed Web of Science ®Google Scholar
• CitriAYardenYEGF-ERBB signalling: towards the systems levelNat Rev Mol Cell Biol2006750551616829981
   PubMed Web of Science ®Google Scholar
• HynesNELaneHAERBB receptors and cancer: the complexity of targeted inhibitorsNat Rev Cancer2005534135415864276
   PubMed Web of Science ®Google Scholar
• FerraroBBeplerGSharmaSEGR1 predicts PTEN and survival in patients with non-small-cell lung cancerJ Clin Oncol2005231921192615774784
   PubMed Web of Science ®Google Scholar
• HauraEBZhengZSongLActivated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancerClin Cancer Res2005118288829416322287
   PubMed Web of Science ®Google Scholar
• LoHWHsuSCAli-SeyedMNuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathwayCancer Cell2005757558915950906
   PubMed Web of Science ®Google Scholar
• ShepherdFARodrigues PereiraJCiuleanuTErlotinib in previously treated non-small-cell lung cancerN Engl J Med200535312313216014882
   PubMed Web of Science ®Google Scholar
• TsaoMSSakuradaACutzJCErlotinib in lung cancer - molecular and clinical predictors of outcomeN Engl J Med200535313314416014883
   PubMed Web of Science ®Google Scholar
• HerbstRSPragerDHermannRTRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancerJ Clin Oncol2005235892589916043829
   PubMed Web of Science ®Google Scholar
• GatzemeierUPluzanskaASzczesnaAPhase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation TrialJ Clin Oncol2007251545155217442998
   PubMed Web of Science ®Google Scholar
• BaselgaJNew therapeutic agents targeting the epidermal growth factor receptorJ Clin Oncol20001854S59S11060328
   PubMed Web of Science ®Google Scholar
• GoldsteinNIPrewettMZuklysKBiological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft modelClin Cancer Res19951131113189815926
   PubMed Web of Science ®Google Scholar
• BaselgaJThe EGFR as a target for anticancer therapy – focus on cetuximabEur J Cancer200137Suppl 4S16S2211597400
   PubMed Web of Science ®Google Scholar
• BaselgaJTargeting the epidermal growth factor receptor: a clinical realityJ Clin Oncol200119S41S44
   Web of Science ®Google Scholar
• BaselgaJA review of EGFR targeted therapyClin Adv Hematol Oncol2003121821916224409
   PubMedGoogle Scholar
• BaselgaJPfisterDCooperMRPhase I studies of antiepidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatinJ Clin Oncol20001890491410673534
   PubMed Web of Science ®Google Scholar
• RobertFEzekielMPSpencerSAPhase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancerJ Clin Oncol2001193234324311432891
   PubMed Web of Science ®Google Scholar
• LiSSchmitzKRJeffreyPDStructural basis for inhibition of the epidermal growth factor receptor by cetuximabCancer Cell2005730131115837620
   PubMed Web of Science ®Google Scholar
• MarshallJClinical implications of the mechanism of epidermal growth factor receptor inhibitorsCancer20061071207121816909423
   PubMed Web of Science ®Google Scholar
• SigismundSArgenzioETosoniDClathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradationDev Cell20081520921918694561
   PubMed Web of Science ®Google Scholar
• HolbroTHynesNEErbB receptors: directing key signaling networks throughout lifeAnnu Rev Pharmacol Toxicol20044419521714744244
   PubMed Web of Science ®Google Scholar
• FanZShangBYLuYReciprocal changes in p27(Kip1) and p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptorsClin Cancer Res19973194319489815583
   PubMed Web of Science ®Google Scholar
• PengDFanZLuYAnti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145Cancer Res199656366636698706005
   PubMed Web of Science ®Google Scholar
• WuXRubinMFanZInvolvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibodyOncogene199612139714038622855
   PubMed Web of Science ®Google Scholar
• ZandiRLarsenABAndersenPMechanisms for oncogenic activation of the epidermal growth factor receptorCell Signal2007192013202317681753
   PubMed Web of Science ®Google Scholar
• KuraiJChikumiHHashimotoKAntibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell linesClin Cancer Res2007131552156117332301
   PubMed Web of Science ®Google Scholar
• FanZBaselgaJMasuiHAntitumor effect of antiepidermal growth factor receptor monoclonal antibodies pluscis-diamminedichloroplatinum on well established A431 cell xenograftsCancer Res199353463746428402640
   PubMed Web of Science ®Google Scholar
• HoffmannTHafnerDBalloHAntitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma linesAnticancer Res199717441944259494544
   PubMed Web of Science ®Google Scholar
• BaselgaJNortonLAlbanellJRecombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenograftsCancer Res199858282528319661897
   PubMed Web of Science ®Google Scholar
• InoueKSlatonJWPerrottePPaclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinomaClin Cancer Res200064874488411156247
   PubMed Web of Science ®Google Scholar
• BlagosklonnyMVSchulteTNguyenPTaxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathwayCancer Res199656185118548620503
   PubMed Web of Science ®Google Scholar
• GarciaRFranklinRAMcCubreyJAEGF induces cell motility and multi-drug resistance gene expression in breast cancer cellsCell Cycle200652820282617172846
   PubMed Web of Science ®Google Scholar
• YunCHMengwasserKETomsAVThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProc Natl Acad Sci U S A20081052070207518227510
   PubMed Web of Science ®Google Scholar
• WangSENarasannaAPerez-TorresMHER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitorsCancer Cell200610253816843263
   PubMed Web of Science ®Google Scholar
• RothenbergSMEngelmanJALeSModeling oncogene addiction using RNA interferenceProc Natl Acad Sci U S A2008105124801248418711136
   PubMed Web of Science ®Google Scholar
• EngelmanJAZejnullahuKMitsudomiTMET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingScience20073161039104317463250
   PubMed Web of Science ®Google Scholar
• MorgilloFKimWYKimESImplication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinibClin Cancer Res2007132795280317473213
   PubMed Web of Science ®Google Scholar
• AmadoRGWolfMPeetersMWild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancerJ Clin Oncol2008261626163418316791
   PubMed Web of Science ®Google Scholar
• KarapetisCSKhambata-FordSJonkerDJK-ras mutations and benefit from cetuximab in advanced colorectal cancerN Engl J Med20083591757176518946061
   PubMed Web of Science ®Google Scholar
• LievreABachetJBLe CorreDKRAS mutation status is predictive of response to cetuximab therapy in colorectal cancerCancer Res2006663992399516618717
   PubMed Web of Science ®Google Scholar
• PaoWWangTYRielyGJKRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinibPLoS Med20052e1715696205
   PubMed Web of Science ®Google Scholar
• PirkerRPereiraJRSzczesnaACetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialLancet20093731525153119410716
   PubMed Web of Science ®Google Scholar
• O’ByrneKBondarenkoIBarriosCMolecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX studyJ Clin Oncol2009 ASCO Annual Meeting Proceedings. J Clin Oncol20092715s(suppl; abstr 8007).
   Google Scholar
• CappuzzoFLigorioCToschiLEGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)J Thorac Oncol2007242342917473658
   PubMed Web of Science ®Google Scholar
• HirschFRVarella-GarciaMCappuzzoFCombination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinibAnn Oncol20071875276017317677
   PubMed Web of Science ®Google Scholar
• HirschFRHerbstRSOlsenCIncreased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapyJ Clin Oncol2008263351335718612151
   PubMed Web of Science ®Google Scholar
• CernyTBarnesDMHasletonPExpression of epidermal growth factor receptor (EGF-R) in human lung tumoursBr J Cancer1986542652693017396
   PubMed Web of Science ®Google Scholar
• ThieneltCDBunnPAJrHannaNMulticenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancerJ Clin Oncol2005238786879316246975
   PubMed Web of Science ®Google Scholar
• RobertFBlumenscheinGHerbstRSPhase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancerJ Clin Oncol2005239089909616301597
   PubMed Web of Science ®Google Scholar
• ButtsCABodkinDMiddlemanELRandomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancerJ Clin Oncol2007255777578418089875
   PubMed Web of Science ®Google Scholar
• SpigelDGrecoFBurrisHDocetaxel, gemcitabine, and cetuximab in untreated advanced non-small cell lung cancer: P3–144. 12th World Conference on Lung Cancer; 2007 September 2–6J Thorac OncolSeoul, Korea: 20072(8)Suppl 4S740S741
   Google Scholar
• BelaniCPSchreederMTSteisRGCetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 studyCancer20081132512251718816622
   PubMed Web of Science ®Google Scholar
• BorghaeiHLangerCJMillensonMPhase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017J Thorac Oncol200831286129218978564
   PubMed Web of Science ®Google Scholar
• SalehMSocinskiMTrentDRandomized phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small cell lung cancer (NSCLC). ASCO Annual Meeting Proceedings Part IJ Clin Oncol20072518SJune 20 Suppl:Abstract 7586.
   Google Scholar
• HerbstRChanskyKKellyKA phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): Final report of SWOG 0342. ASCO Annual Meeting Proceedings Part IJ Clin Oncol20072518SJune 20 Suppl: Abstract 7545.
   Google Scholar
• BradfordDSocinskiMLaRoccaRPhase II trial of carboplatin plus cetuximab for the treatment of stage IIIB/IV non-small cell lung cancer (NSCLC). ASCO Annual Meeting Proceedings Part IJ Clin Oncol20072518SJune 20 Suppl:Abstract 18005.
   Google Scholar
• LilenbaumRWangXGuLPhase II randomized trial of docetaxel plus cetuximab or bortezomib in patients with advanced NSCLC and performance status (PS) 2-CALGB 30402. ASCO Annual Meeting Proceedings Part IJ Clin Oncol20072518SJune 20 Suppl:Abstract 7595.
   Google Scholar
• RosellRRobinetGSzczesnaARandomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancerAnn Oncol20081936236917947225
   PubMed Web of Science ®Google Scholar
• PirkerRSzczesnaAvon PawelJFLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)J Clin Oncol200826(May 20 Suppl):Abstract 3.
   Web of Science ®Google Scholar
• LynchTTaralPLukeDA randomized multicenter phase III study of cetuximab (Erbitux®) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/metastatic Non-small cell lung cancer (NSCLC): B3–03J Thorac Oncol20072(8)Suppl 4S340S341
   Web of Science ®Google Scholar
• HannaNLilenbaumRAnsariRPhase II trial of cetuximab in patients with previously treated non-small-cell lung cancerJ Clin Oncol2006245253525817114658
   PubMed Web of Science ®Google Scholar
• JalalSWaterhouseDEdelmanMPemetrexed plus cetuximab in patients (pts) with recurrent non-small cell lung cancer (NSCLC): A phase I–IIa dose-ranging study from the Hoosier Oncology Group. ASCO Annual Meeting Proceedings Part IJ Clin Oncol20072518SJune 20 Suppl:Abstract 7698.
   Google Scholar
• KimESMauerAMWilliamWNJrA phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall-cell lung cancerCancer2009
   Web of Science ®Google Scholar
• BonnerJAHarariPMGiraltJRadiotherapy plus cetuximab for squamous-cell carcinoma of the head and neckN Engl J Med200635456757816467544
   PubMed Web of Science ®Google Scholar
• HughesSLiongJMiahASafety study of induction chemotherapy and synchronous radiotherapy (RT) and cetuximab in stage III nonsmall cell lung cancer (NSCLC): SCRATCH (Cohort I). ASCO Annual Meeting Proceedings Part IJ Clin Oncol20072518SJune 20 Suppl: Abstract 18032.
   Google Scholar
• BlumenscheinGPaulusRCurranWA phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): A report of the 2 year and median survival (MS) for the RTOG 0324 trialJ Clin Oncol200826(May 20 Suppl):Abstract 7516.
   Google Scholar
• GovindanRBogartJWangXA phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407–Early evaluation of feasibility and toxicityJ Clin Oncol200826(May 20 Suppl):Abstract 7518.
   Web of Science ®Google Scholar
• SaifMWKimRIncidence and management of cutaneous toxicities associated with cetuximabExpert Opin Drug Saf2007617518217367263
   PubMed Web of Science ®Google Scholar
• Perez-SolerRSaltzLCutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?J Clin Oncol2005235235524616051966
   PubMed Web of Science ®Google Scholar
• AlexandrescuDTVaillantJGDasanuCAEffect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitorsClin Exp Dermatol200732717417034418
   PubMed Web of Science ®Google Scholar
• ChouLSGareyJOishiKManaging dermatologic toxicities of epidermal growth factor receptor inhibitorsClin Lung Cancer20068Suppl 1S15S2217239286
   PubMed Web of Science ®Google Scholar
• DeslandresMSibaudVChevreauCCutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitorsAnn Dermatol Venereol Spec200811624
   Google Scholar
• RheeJOishiKGareyJManagement of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agentsClin Colorectal Cancer20055Suppl 2S101S10616336749
   PubMedGoogle Scholar
• ScopeAAgeroALDuszaSWRandomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruptionJ Clin Oncol2007255390539618048820
   PubMed Web of Science ®Google Scholar
• ThomasMCetuximab: adverse event profile and recommendations for toxicity managementClin J Oncol Nurs2005933233815973844
   PubMedGoogle Scholar
• ChungCHMirakhurBChanECetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactoseN Engl J Med200835811091101718337601
   PubMed Web of Science ®Google Scholar
• O’NeilBHAllenRSpigelDRHigh incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic historyJ Clin Oncol2007253644364817704414
   PubMed Web of Science ®Google Scholar
• GroenestegeWMThebaultSvan der WijstJImpaired baso-lateral sorting of pro-EGF causes isolated recessive renal hypomagnesemiaJ Clin Invest20071172260226717671655
   PubMed Web of Science ®Google Scholar
• WagnerCADisorders of renal magnesium handling explain renal magnesium transportJ Nephrol20072050751017918133
   PubMed Web of Science ®Google Scholar
• NCI: Cetuximab in Lung Cancer | Open Studies. http://clinicaltrials.gov/ Accessed March 01, 2009.
   Google Scholar